BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE (603392) Stock Price, Fundamentals & Analysis
Price
26.38 CNY
-2.04%
Last trade: Sep 24, 2026, 03:00 PM GMT+8
Updated: Sep 27, 2026, 05:31 PM GMT+8
Price history
Over the past year 603392 traded between 24.97 CNY and 58.11 CNY, closing at 26.38 CNY on Sep 24, 2026.
Key statistics
| Market cap | 33.35B CNY |
|---|---|
| Forward P/E | 46.3 |
| EPS (TTM) | -0.3 CNY |
| Dividend yield | 0% |
| Annual dividend | 0 CNY |
| Ex-dividend date | Jun 3, 2024 |
| Payout ratio | 0% |
| 52-week range | 24.7 – 58.66 |
| 52-week change | -52.5% |
| Beta | 0.74 |
| Price / book | 2.84 |
| Revenue (TTM) | 2.02B CNY |
| Revenue growth (YoY) | 18.6% |
| Gross margin | 41.9% |
| Operating margin | -23% |
| Profit margin | -18.9% |
| Return on equity | -3.3% |
| Debt / equity | 2.7 |
| Volume | 5,942,538 |
| Average volume | 6,971,127 |
| Exchange | Shanghai |
Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,116
- Headquarters
- Beijing, China
- Website
- ystwt.com
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. The company offers in vitro diagnostics and automated laboratory instruments, including Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers; chemiluminescence and biochemistry tests, including novel diagnostic tests for detection of Hepatitis virus infections; P-85 Ab for nasopharyngeal cancer screening; and TB-IGRA for large population screening. It also provides diagnostic assays, such as high-value Hepatitis B core antibody tests, Hepatitis E Urine tests, Hepatitis D virus detection, IL-6, HIV 4th generation CLIA, Helicobacter pylori antibody, gastrin-17, and soluble transferrin receptor assays; and enzyme-linked immunosorbent assay (ELISA), colloidal gold, molecular, clinical laboratory quality control products, and bioactive materials for various infectious diseases, such as HIV, Hepatitis, Tuberculosis, and Influenza A/B.
Overview
What 603392 does
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE (603392) is a stock listed on the Shanghai Stock Exchange in the Healthcare sector, within the Biotechnology industry. The company is headquartered in Beijing, China, and employs 4,116 people. It researches, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. Its product range includes in vitro diagnostics and automated laboratory instruments, chemiluminescence and biochemistry tests, and assays for infectious diseases such as Hepatitis, HIV, Tuberculosis, and Influenza A/B.
Key numbers explained
- The current price is 26.38 CNY, down 2.04% today.
- The market capitalization of 33.35B CNY reflects the total market value of all outstanding shares.
- The forward P/E ratio of 46.3 compares the price to expected future earnings; a higher number can indicate higher growth expectations.
- The dividend yield is 0%, and the share of earnings paid out as dividends is 0%, meaning the company does not currently pay a dividend.
- The beta of 0.74 suggests the stock has historically been less volatile than the overall market.
- The price-to-book ratio of 2.84 compares the market price to the company's book value per share.
- The debt-to-equity ratio of 2.7 indicates the company uses more debt than equity to finance its assets.
What to watch
Investors tracking 603392 may monitor its revenue growth, which was 18.6% year over year to 2.02B CNY in trailing twelve months. The company is part of the Shanghai Stock Exchange and can be compared to peers such as WuXi AppTec (603259) or Shanghai Pharmaceuticals Holding (601607). General factors for this kind of stock include regulatory developments for diagnostics and vaccines, research and development pipeline updates, and broader trends in the Healthcare sector. The stock's 52-week range of 24.7 – 58.66 and the -52.5% price change over the last year highlight the importance of considering long-term price history.
Latest news & filings
No recent headlines.
Frequently asked questions
Does 603392 pay a dividend?
No. The dividend yield is 0% and the share of earnings paid out as dividends is 0%, so the company does not currently pay a dividend.
What is the 603392 P/E ratio?
The forward P/E ratio, based on expected earnings, is 46.3.
Where can I buy 603392?
It is listed on the Shanghai Stock Exchange under the symbol 603392.
What does BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE do?
It researches, develops, produces, and sells biological diagnostic tests and vaccines, including instruments and assays for infectious diseases.
How volatile is 603392 compared to the market?
Its beta is 0.74, which typically means it is less volatile than the overall market.
Related
More on 603392
Track 603392 in your portfolio
Hold 603392 at XTB, IBKR, Tradeville, Revolut or Trading 212? InvestPane brings every broker into one dashboard — allocation, performance and dividends in one place.
Start free